An observational study in Liver Cirrhosis and Portal Hypertension, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-21.
Sponsored by Assistance Publique - Hôpitaux de Paris · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Liver Cirrhosis by Assistance Publique - Hôpitaux de Paris — 4 open to participants now, 4 under way, none of them phase 3. Liver Cirrhosis · Assistance Publique - Hôpitaux de Paris.
Among the 16 studies in Liver Cirrhosis by Assistance Publique - Hôpitaux de Paris, this one is the 9th largest by planned enrollment of the 10 observational ones that give a count, is one of 2 that started in 2026, is one of 10 observational ones, and was the 15th registered.
1,303 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.
Browse Liver Cirrhosis studies →4 of the 16 studies in Liver Cirrhosis by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
By country, each count listing its studies:
Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 45 is below the median of 172 across 528 observational studies indexed under Liver Cirrhosis.
Median enrollment 242 across the 6 interventional studies, 226 across the 10 observational. Of the 11 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
3 of the studies in Liver Cirrhosis by Assistance Publique - Hôpitaux de Paris that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07439939Assistance Publique - Hôpitaux de ParisExploration of Systemic and Portal Hemostasis in Patients Undergoing Transjugular Intrahepatic Portosystemic Shunt Placement | 2027-06-09 |
| NCT06755632Assistance Publique - Hôpitaux de ParisScreening of Patients With Hepatic Fibrosis or Cirrhosis B and C | 2027-06-19 |
| NCT07028112Assistance Publique - Hôpitaux de ParisImpact of Iron Overload on the Incidence of Liver Complications in Long-Term Survivors (≥10 Years) of Allogeneic Hematopoietic Stem-Cell Transplantation. | 2027-08-20 |
Add all 3 to your calendar (.ics) → With an account.
Among the 16 studies in Liver Cirrhosis by Assistance Publique - Hôpitaux de Paris, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Portal vein thrombosis is defined as non-tumoural obstruction of the portal vein or one of its branches. Its incidence is 0.7 to 2.7 per 100,000 patient-years in the general population, and 4.6 per 100 patient-years in patients with cirrhosis. Histological modificaitions fo the portal vein wall and haemostatic changes have been described in cirrhotic patients. The contribution of these changes, both systemic and local, to the development of portal vein thrombosis is debated. One of the hypotheses put forward on the genesis of portal vein thrombosis is as follows: certain bacterial translocations from the digestive tract, promoted by portal hypertension, contribute to endothelial activation resulting in the release of von Willebrand factor and factor VIII, as well as platelet activation and the coagulation cascade, which is dysregulated by cirrhosis and underlying changes in haemostatic balance. Inflammatory phenomena and NETosis may also be involved. Studies suggest that cirrhotic patients have lesions of the glycocalyx located in the portal area, which may be involved in the development of portal vein thrombosis. Patients with cirrhosis may benefit from the placement of a transjugular intrahepatic portosystemic shunt (TIPS). During the TIPS placement procedure, blood is drawn from the internal jugular vein and the portal vein, allowing for parallel biological analyses. The assumption of this study is that haemostasis and inflammation are disrupted differently at the systemic and portal levels in cirrhotic patients.
Portal vein thrombosis is defined as non-tumoural obstruction of the portal vein or one of its branches. Its incidence is 0.7 to 2.7 per 100,000 patient-years in the general population, and 4.6 per 100 patient-years in patients with cirrhosis. Portal vein thrombosis associated with cirrhosis, which is most often non-occlusive (70%), is characterised by histological changes in the portal vein wall and the presence of an intraluminal thrombus.
In cirrhotic patients, histological changes are described at the portal level. In response to portal hypertension, the calibre of the portal vein, where circulation is at low pressure and high compliance, increases. In response to this mechanical stress, intimal hypertrophy and fibroblast proliferation are observed. In cases of portal vein thrombosis, these changes are more pronounced. Changes in haemostatic balance are also observed in these patients. Thrombocytopenia and decreased synthesis of coagulation factors on the one hand, and decreased coagulation cascade and fibrinolytic regulatory factors on the other, contribute to creating a new fragile haemostatic balance. The contribution of these changes, both systemic and local, to the development of portal vein thrombosis is debated.
One of the hypotheses put forward on the genesis of portal vein thrombosis is as follows: certain bacterial translocations from the digestive tract, promoted by portal hypertension, contribute to endothelial activation resulting in the release of von Willebrand factor (VWF) and factor VIII, as well as platelet activation and the coagulation cascade, which is dysregulated by cirrhosis and underlying changes in haemostatic balance.
This hypothesis is supported by several studies showing that cirrhotic patients have higher portal than systemic levels of VWF, factor VIII and lipopolysaccharides. Inflammatory phenomena and NETosis may also be involved.
The vascular endothelial surface is covered by the glycocalyx, with antithrombotic and anti-inflammatory effects that regulates vascular permeability. The endothelial glycocalyx has three major components: proteoglycans binding to the endothelial membrane, sulphated glycosaminoglycans bound laterally to proteoglycans, and plasma proteins. Studies suggest that cirrhotic patients have lesions of the glycocalyx located in the portal area, which may be involved in the development of portal vein thrombosis. Patients with cirrhosis may benefit from the placement of a transjugular intrahepatic portosystemic shunt (TIPS).
During the TIPS placement procedure, blood is drawn from the internal jugular vein and the portal vein, allowing for parallel biological analyses.
The assumption of this study is that haemostasis and inflammation are disrupted differently at the systemic and portal levels in cirrhotic patients. To our knowledge, studies conducted to date have not investigated haemostasis under flow conditions, which are more physiological than static investigations.
Patients with cirrhosis, regardless of the underlying cause, undergoing TIPS placement, regardless of the indication.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Area Under the Curve (AUC) of primary hemostasis assessed by T-TAS®01 at 10 minutes
The primary outcome measure is the area under the curve (AUC) obtained at 10 minutes of perfusion during the assessment of primary hemostasis using the T-TAS®01 microfluidic system. Measurements are performed with PL chips coated with collagen. Under these conditions, thrombus formation is dependent on von Willebrand factor, allowing evaluation of primary hemostasis at the systemic and portal levels in patients with cirrhosis.
Time frame: At 10 minutes of perfusion during the T-TAS®01 primary hemostasis assessment procedure
Time to reach 10 kPa above baseline pressure in the T-TAS®01 system
Time required to reach a pressure of 10 kPa above baseline during perfusion in the T-TAS®01 microfluidic system, measured on systemic and portal blood samples
Time frame: At the time of TIPS placement
Time to reach 60 kPa above baseline pressure in the T-TAS®01 system
Time required to reach a pressure of 60 kPa above baseline during perfusion in the T-TAS®01 microfluidic system, measured on systemic and portal blood samples
Time frame: At the time of TIPS placement
Conventional coagulation parameters at systemic and portal levels
Prothrombin time, activated partial thromboplastin time ratio, factor V, fibrinogen (Clauss method), antithrombin, factor VIII, von Willebrand factor antigen and activity, and ADAMTS-13 activity measured in systemic and portal blood samples
Time frame: At the time of TIPS placement
Fibrinolysis parameters at systemic and portal levels
Tissue plasminogen activator antigen and activity, plasminogen activator inhibitor-1 antigen and activity, D-dimers, protease nexin-1, and global fibrinolytic capacity measured in systemic and portal blood samples
Time frame: At the time of TIPS placement
Complete blood count parameters at systemic and portal levels
Complete blood count parameters including hemoglobin, hematocrit, leukocytes, and platelet count measured in systemic and portal blood samples
Time frame: At the time of TIPS placement
ROTEM® coagulation parameters at systemic and portal levels
ROTEM® EXTEM and INTEM parameters including clotting time, clot formation time, amplitude at 5 minutes, and maximum clot firmness measured in systemic and portal blood samples
Time frame: At the time of TIPS placement
Thrombin generation parameters at systemic and portal levels
Thrombin generation test parameters including lag time, time to peak, peak thrombin, endogenous thrombin potential, velocity index, and end of test time, assessed with and without thrombomodulin in systemic and portal samples
Time frame: At the time of TIPS placemen
Inflammatory biomarkers at systemic and portal levels
Albumin, C-reactive protein, interleukin-6, and lipopolysaccharides measured in systemic and portal blood samples
Time frame: At the time of TIPS placement
Endothelial and glycocalyx biomarkers at systemic and portal levels
Angiopoietin-1, angiopoietin-2, glycosaminoglycans, heparan sulfate, syndecan, soluble thrombomodulin, and soluble P-selectin measured in systemic and portal blood samples
Time frame: At the time of TIPS placement
Markers of thrombo-inflammation and NETosis at systemic and portal levels
Cell-free DNA, citrullinated histone-3, DNA-histone-3 complexes, and DNase activity measured in systemic and portal blood samples
Time frame: At the time of TIPS placement
Child-Pugh score
Assessment of liver disease severity using the Child-Pugh score (range 5-15, higher scores indicate more severe liver disease), measured prior to TIPS placement
Time frame: Prior to TIPS placement
MELD score
Assessment of liver disease severity using the Model for End-Stage Liver Disease (MELD) score, measured prior to TIPS placement
Time frame: Prior to TIPS placement
Portal-systemic pressure gradient
Measurement of the porto-systemic pressure gradient prior to TIPS placement
Time frame: Prior to TIPS placement
Occurrence of TIPS thrombosis at Day 90
Occurrence of partial or complete thrombosis of the TIPS or a portal vein branch within 90 days after TIPS placement
Time frame: Up to 90 days after TIPS placement
Need for TIPS revision or recalibration at Day 90
Need for TIPS revision or recalibration within 90 days after TIPS placement
Time frame: Up to 90 days after TIPS placement
Major clinical events at Day 90
Occurrence of liver transplantation, gastrointestinal bleeding, or TIPS infection within 90 days after TIPS placement
Time frame: Up to 90 days after TIPS placement
Started Mar 2026 (actual). Primary completion is estimated for Jun 2027, 15 months after the start.
Of 231 non-industry observational studies under Liver Cirrhosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 71. This study's planned 15 months is below that.
Counting every sponsor, half of 247 studies reached it within 47 months; a quarter within 18 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →